20 May 2024 in Leukemia & Lymphoma
8 May 2024 in Clinical Case Reports
Key Clinical Message: Paroxysmal nocturnal hemoglobinuria is a rare disease with the incidence ranging from 0.08 to 0.57 per 100,000 person‐years. Up to 25% of cases in women are detected during pregnancy. We report two cases of successful pregnancy outcomes in patients treated with eculizumab, pointing out the importance of interdisciplinary approach in these high‐risk pregnancies.
1 January 2022 in Medicinski Pregled
Introduction. The Myeloproliferative Neoplasms are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by increased proliferation of the myeloid lineages in the bone marrow. A particular clinical challenge is presented by certain situations in patients with myeloproliferative Neoplasms, which we do not encounter daily. For this reason, in this paper, we will emphasize the approach to overcoming obstacles in patients with Myeloproliferative Neoplasms in specific settings, like pregnancy. Pregnancy with Philadelphia chromosome-negative Myeloproliferative Neoplasms has been reported to be associated with maternal thrombosis, hemorrhage, and placental dysfunction leading to fetal growth restriction or loss. Thrombocytosis, leucocytosis, high level of hematocrit, activation of Platelets, leucocytes, and circulating pro-thrombotic are connected with the pathogenesis of thrombosis in MPNs With survival expectations similar to age-matched controls and excellent response and worldwide access to tyrosine kinase inhibitors, family planning is increasingly important for many patients with chronic myeloid leukemia. All patients were managed by a multidisciplinary team of physicians with obligatory hematological and gynecologistsobstetrician consultations.
1 January 2024 in Srpski medicinski casopis Lekarske komore
Introduction: According to the results of previous research, it was found that the dysfunction of the insulin-like growth factor (IGF) system, which is the basis of insulin resistance with hyperinsulinemia, acts as a proliferative tumor factor, and its neoplastic potential is also exhibited in multiple myeloma. Study aim: The study aims to determine whether there is an association between insulin resistance in patients newly diagnosed with multiple myeloma (NDMM) and the achieved therapeutic response after induction chemotherapy. Materials and methods: The prospective study included 35 NDMM patients (60% women and 40% men), treated at the Clinical Center of Vojvodina Clinic for Hematology. Glycemia and insulinemia levels were determined after fasting and postprandially, upon which the values of HOMA-IRIf (after fasting) and HOMA-IRIpp (postprandially) were calculated. HOMA-IRI values > 2.2 were the criteria for insulin resistance. The analyses were performed twice - before the initial chemotherapy and after the completion of the treatment. The therapeutic response was evaluated according to the criteria of the Serbian Myeloma Group (SMG) and the International Myeloma Working Group IMWG). Statistical analyses were performed in the SPSS program, Version 22. Results: The average patient age was 63.85 years. In total, 86% of patients responded favorably to the therapy. The average value of HOMA-IRIf before treatment was 1.82 ± 0.79 and it was 1.80 ± 0.72 after therapy. The central median value of HOMA-IRIpp before treatment was 5.46, with an interquartile range of 1.07 - 20.57, and after treatment, it was 5.86 with an interquartile range of 1.22 - 28.22. A significant negative correlation between HOMA-IRIf after applied treatment and achieved therapeutic response was observed, (p = 0.040). Conclusion: Active concomitant therapy of insulin resistance in NDMM could improve the response to applied antimyeloma treatment.
1 January 2024 in Srpski medicinski casopis Lekarske komore
Introduction: Ferroptosis, mentioned as such for the first time in 2012 by Dixon et al., is an iron-dependent type of cell death that occurs in the presence of lipid peroxides. The mechanism of the process and the signaling pathways involved in it differ from the previously known apoptosis, necrosis, and autophagy. An inflammatory reaction also occurs, which further distinguishes this type of cell death from apoptosis. Ferrostatin inhibits this process. Methods: A review of the literature obtained by searching the Medline database was performed, with a special focus on studies concerned with the importance of ferroptosis in clinical medicine, primarily hematology. Results: Iron metabolism in malignant and healthy cells differs. Malignant cells tolerate oxidative stress well and avoid ferroptosis. According to literature data, various tested agents stimulate ferroptosis and thus become possible therapeutic agents. Some genes linked to iron metabolism have shown prognostic significance in patients with diffuse large B-cell lymphoma. Conclusion: The discovery of new mechanisms of cell death and the signaling pathways involved in this process leads to potentially new target therapy. Although promising, these results require validation through further research.